ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.

Andrea Galbiati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.